As of November 30, 2025, no injectable or infusion-based age-reversal therapy based on stem cells or Yamanaka-style partial reprogramming is approved or commercially available to average consumers; such approaches remain preclinical or at best in very early, disease-specific human trials (e.g., Life Biosciences’ planned 2025 optic-nerve trial and YouthBio’s preparatory steps toward an Alzheimer’s trial). (p05.org) Major reviews note that partial reprogramming with Yamanaka factors has extended lifespan in mice but has not yet entered human trials for aging itself, and aging is not recognized by regulators such as the FDA as a disease indication that can be directly targeted, further slowing development of any broad age-reversal therapy. (longevity.technology) Medical/science overviews likewise emphasize that, as of mid‑2025, there are no approved Yamanaka- or MPTR-based anti-aging treatments available to the public; any offerings are experimental or speculative. (mededgemea.com) However, Friedberg’s prediction is about whether such a therapy will exist by roughly 2035, so with nearly a decade remaining on that timeline, there is not yet enough information to say whether it will ultimately be right or wrong.